Real-world 10-year retrospective study of the guidelines for diagnosis and treatment of primary liver cancer in China

doi:10.4251/wjgo.v15.i5.859

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1909)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-7) series.

Item

Count

PDF

WORD

HTML

1118

Figures (1-4)

148

Tables (1-7)

112

Sum=1480

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

132

Download

297

Sum=429

May 15, 2023 (publication date) through May 2, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. May 15, 2023; 15(5): 859-877
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.859

Table 4 Analysis of treatment compliance among patients with hepatocellular carcinoma according to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China, n (%)

Variable	Total (n = 3022)	Compliance with guideline-recommended treatment		χ²	P value
Variable	Total (n = 3022)	Yes, n = 2212 (73.20%)	No, n = 810 (26.80%)	χ²	P value
Sex				3.191	0.074
Male	2487 (82.30)	1837 (83.05)	650 (80.25)
Female	535 (17.70)	375 (16.95)	160 (19.75)
Age				0.652	0.419
< 50	884 (29.25)	656 (29.66)	228 (28.15)
≥ 50	2138 (70.75)	1556 (70.34)	582 (71.85)
Chronic hepatitis				2.046	0.309
HBV	2694 (89.15)	1979 (89.47)	715 (88.27)
HCV	142 (4.70)	96 (4.34)	46 (5.68)
Mixed	45 (1.49)	36 (1.63)	9 (1.11)
None	141 (4.66)	101 (4.56)	40 (4.94)
AFP (ng/mL)				1.859	0.395
≤ 20	1094 (36.20)	786 (35.53)	308 (38.02)
20–400	757 (25.05)	555 (25.09)	202 (24.94)
> 400	1171 (38.75)	871 (39.38)	300 (37.04)
Child–Pugh grade				59.828	0.000^a
A	2191 (72.50)	1687 (76.27)	504 (62.22)
B	737 (24.39)	470 (21.25)	267 (32.96)
C	94 (3.11)	55 (2.49)	39 (4.81)
CNLC				74.941	0.000^a
Early stage (Ia, Ib, and IIa)	1127 (37.29)	910 (41.14)	217 (26.79)
Middle stage (IIb and IIIa)	1439 (47.62)	1028 (46.47)	411 (50.74)
Late stage (IIIb and IV)	456 (15.09)	274 (12.39)	182 (22.47)

^aP < 0.01.

HBV: Hepatitis B virus; HCV: Hepatitis C virus; Mix: HBV complicated with HCV; CNLC: China Liver Cancer staging; AFP: Alpha-fetoprotein.

Citation: Yan YW, Liu XK, Zhang SX, Tian QF. Real-world 10-year retrospective study of the guidelines for diagnosis and treatment of primary liver cancer in China. World J Gastrointest Oncol 2023; 15(5): 859-877
URL: https://www.wjgnet.com/1948-5204/full/v15/i5/859.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i5.859